In several diseases, low muscle mass has been revealed as an unfavorable prognostic factor for out come. Whet her this holds true in patients with solid malignancies as well has increasingly been explored recently. However, this research field is severely hampered by a lack of consensus on how to determine muscle mass in cancer patients and on the definition of low muscle mass. Consequently, the prevalence of low muscle mass varies widely across several studies. Never the less, most studies show that, in patients with solid malignancies, low muscle mass is associated with a poor out come. In the future, more research is needed to get better insight into the best method to determine muscle mass, the exact prognostic value of low muscle mass in diverse tumor types and stages, pathophysiology of low muscle mass in patients with cancer, and ways to intervene and improve muscle mass in patients. This review addresses the current literature on the importance of muscle mass in cancer patients and the methods of muscle measurement.Implications for Practice:
An increasing number of studies
underline the clinical value of low muscle mass as a prognostic factor
for adverse outcomes
in cancer patients. However, studies show large
heterogeneity because of the lack of a standardized approach to measure
mass and the lack of reference populations. As a
result, the interpretation of data and further progress are severely
hindering the implementation of muscle
measurement in oncological care. This review summarizes the methods of
muscle mass in cancer patients, the difference
between underlying syndromes such as sarcopenia and cachexia, and the
with clinical outcomes described so far.
Bibliographical note©AlphaMed Press.
- Low muscle mass